Drug Profile
Inosine - Polysan
Alternative Names: Riboxinum; RuniholLatest Information Update: 22 Feb 2022
Price :
$50
*
At a glance
- Originator POLYSAN
- Class Purine nucleosides; Ribonucleosides; Small molecules
- Mechanism of Action Cytokine modulators; Inflammation mediator modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Non-alcoholic fatty liver disease
Most Recent Events
- 22 Feb 2022 Discontinued - Phase-II for Non-alcoholic fatty liver disease in Russia (PO)
- 10 Oct 2018 Scientific Technological Pharmaceutical Firm Polysan terminates a phase II trial in Non-alcoholic-fatty-liver-disease in Russia due to low patient recruitment (NCT02930161)
- 01 Jun 2016 Phase-II clinical trials in Non-alcoholic-fatty-liver-disease in Russia (PO)